• Earlier this week, Praxis Precision Medicines announced that the FDA granted Breakthrough Therapy Designation to elsunersen (PRAX-222) for treating seizures in children with SCN2A developmental and epileptic encephalopathy caused by gain-of-function SCN2A variants, based on positive EMBRAVE Part A trial data.
• The designation, layered on top of multiple US and European rare disease incentives, underscores elsunersen’s potential to address a severe epilepsy with no approved genetically targeted therapies.
• We’ll now explore how this Breakthrough Therapy Designation for elsunersen reshapes Praxis’s investment narrative around its late-stage epilepsy portfolio.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Praxis Precision Medicines Investment Narrative Recap

To own Praxis today, you need to believe its late stage epilepsy and movement disorder programs can translate strong genetics based science into approved therapies, despite zero current revenue and ongoing losses. The new Breakthrough Therapy Designation for elsunersen sharpens that bet, but the near term narrative is still dominated by execution and data risk around the pivotal epilepsy programs, especially after the recent POWER1 miss with vormatrigine.

Among recent announcements, the POWER1 readout for vormatrigine in focal onset seizures is the most relevant counterweight to the elsunersen news. While POWER1 did not meet its primary endpoint, Praxis has paused POWER2 enrollment to reassess the program, which heightens trial risk just as the company leans harder on its rare disease epilepsy assets like elsunersen and relutrigine to carry the investment story.

Yet behind the headline Breakthrough Therapy news, investors should also be aware that...

Praxis Precision Medicines’ narrative projects $1.4 billion revenue and $434.2 million earnings by 2029. This requires earnings to increase by about $760.7 million from -$326.5 million today.

Uncover how Praxis Precision Medicines' forecasts yield a $617.67 fair value, a 88% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were modeling Praxis revenue jumping to about US$2.1 billion and earnings near US$783.6 million, even as they flagged that heavy late stage trial spending and potential dilution could strain the cash runway; this elsunersen update may either reinforce that upbeat view or prompt you to question how much risk you are comfortable with across such a wide range of outcomes.

Explore 4 other fair value estimates on Praxis Precision Medicines - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Praxis Precision Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Praxis Precision Medicines' overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.